Literature DB >> 21664078

Efficacy of a pandemic (H1N1) 2009 virus vaccine in pigs against the pandemic influenza virus is superior to commercially available swine influenza vaccines.

W L A Loeffen1, N Stockhofe, E Weesendorp, D van Zoelen-Bos, R Heutink, S Quak, D Goovaerts, J G M Heldens, R Maas, R J Moormann, G Koch.   

Abstract

In April 2009 a new influenza A/H1N1 strain, currently named "pandemic (H1N1) influenza 2009" (H1N1v), started the first official pandemic in humans since 1968. Several incursions of this virus in pig herds have also been reported from all over the world. Vaccination of pigs may be an option to reduce exposure of human contacts with infected pigs, thereby preventing cross-species transfer, but also to protect pigs themselves, should this virus cause damage in the pig population. Three swine influenza vaccines, two of them commercially available and one experimental, were therefore tested and compared for their efficacy against an H1N1v challenge. One of the commercial vaccines is based on an American classical H1N1 influenza strain, the other is based on a European avian H1N1 influenza strain. The experimental vaccine is based on reassortant virus NYMC X179A (containing the hemagglutinin (HA) and neuraminidase (NA) genes of A/California/7/2009 (H1N1v) and the internal genes of A/Puerto Rico/8/34 (H1N1)). Excretion of infectious virus was reduced by 0.5-3 log(10) by the commercial vaccines, depending on vaccine and sample type. Both vaccines were able to reduce virus replication especially in the lower respiratory tract, with less pathological lesions in vaccinated and subsequently challenged pigs than in unvaccinated controls. In pigs vaccinated with the experimental vaccine, excretion levels of infectious virus in nasal and oropharyngeal swabs, were at or below 1 log(10)TCID(50) per swab and lasted for only 1 or 2 days. An inactivated vaccine containing the HA and NA of an H1N1v is able to protect pigs from an infection with H1N1v, whereas swine influenza vaccines that are currently available are of limited efficaciousness. Whether vaccination of pigs against H1N1v will become opportune remains to be seen and will depend on future evolution of this strain in the pig population. Close monitoring of the pig population, focussing on presence and evolution of influenza strains on a cross-border level would therefore be advisable.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21664078     DOI: 10.1016/j.vetmic.2011.05.027

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  11 in total

1.  Relationship between airborne detection of influenza A virus and the number of infected pigs.

Authors:  Cesar A Corzo; Anna Romagosa; Scott A Dee; Marie R Gramer; Robert B Morrison; Montserrat Torremorell
Journal:  Vet J       Date:  2012-11-17       Impact factor: 2.688

2.  Vaccine-mediated protection of pigs against infection with pandemic H1N1 2009 swine influenza A virus requires a close antigenic match between the vaccine antigen and challenge virus.

Authors:  Helen E Everett; Mario Aramouni; Vivien Coward; Andrew Ramsay; Michael Kelly; Sophie Morgan; Elma Tchilian; Laetitia Canini; Mark E J Woolhouse; Sarah Gilbert; Bryan Charleston; Ian H Brown; Sharon M Brookes
Journal:  Vaccine       Date:  2019-03-23       Impact factor: 3.641

3.  Airborne detection and quantification of swine influenza a virus in air samples collected inside, outside and downwind from swine barns.

Authors:  Cesar A Corzo; Marie Culhane; Scott Dee; Robert B Morrison; Montserrat Torremorell
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

4.  Control of a Reassortant Pandemic 2009 H1N1 Influenza Virus Outbreak in an Intensive Swine Breeding Farm: Effect of Vaccination and Enhanced Farm Management Practices.

Authors:  Lapo Mughini-Gras; Maria Serena Beato; Giorgia Angeloni; Isabella Monne; Filippo Buniolo; Federica Zuliani; Matteo Morini; Alberto Castellan; Lebana Bonfanti; Stefano Marangon
Journal:  PLoS Curr       Date:  2015-04-13

5.  European surveillance network for influenza in pigs: surveillance programs, diagnostic tools and Swine influenza virus subtypes identified in 14 European countries from 2010 to 2013.

Authors:  Gaëlle Simon; Lars E Larsen; Ralf Dürrwald; Emanuela Foni; Timm Harder; Kristien Van Reeth; Iwona Markowska-Daniel; Scott M Reid; Adam Dan; Jaime Maldonado; Anita Huovilainen; Charalambos Billinis; Irit Davidson; Montserrat Agüero; Thaïs Vila; Séverine Hervé; Solvej Østergaard Breum; Chiara Chiapponi; Kinga Urbaniak; Constantinos S Kyriakis; Ian H Brown; Willie Loeffen
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

6.  Characterization of Viral Load, Viability and Persistence of Influenza A Virus in Air and on Surfaces of Swine Production Facilities.

Authors:  Victor Neira; Peter Rabinowitz; Aaron Rendahl; Blanca Paccha; Shawn G Gibbs; Montserrat Torremorell
Journal:  PLoS One       Date:  2016-01-12       Impact factor: 3.240

7.  Detection of influenza A virus in aerosols of vaccinated and non-vaccinated pigs in a warm environment.

Authors:  Victor Neira; Matt Allerson; Cesar Corzo; Marie Culhane; Aaron Rendahl; Montserrat Torremorell
Journal:  PLoS One       Date:  2018-05-21       Impact factor: 3.240

8.  The effects of fever on hormone ghrelins, immunoglobulins, and heat shock protein 70 expression after swine flu vaccinations.

Authors:  Suleyman Aydin; Tumer Guven; İbrahim Sahin; Aziz Aksoy; Yalçın Kendir; Mustafa N İlhan; Cihan Citil; Zekiye Catak; Cemal Ustun
Journal:  Endocrine       Date:  2012-04-04       Impact factor: 3.633

Review 9.  Optimal Use of Vaccines for Control of Influenza A Virus in Swine.

Authors:  Matthew R Sandbulte; Anna R Spickler; Pamela K Zaabel; James A Roth
Journal:  Vaccines (Basel)       Date:  2015-01-30

10.  Partial Protection against Porcine Influenza A Virus by a Hemagglutinin-Expressing Virus Replicon Particle Vaccine in the Absence of Neutralizing Antibodies.

Authors:  Meret E Ricklin; Nathalie J Vielle; Sylvie Python; Daniel Brechbühl; Beatrice Zumkehr; Horst Posthaus; Gert Zimmer; Artur Summerfield
Journal:  Front Immunol       Date:  2016-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.